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Abstract
Summary This multi-center, prospective, open-label, observa-
tional study evaluated the effects of once-monthly
minodronate (50 mg) on treatment persistence, bone turnover
markers, bone mineral density, low back pain, and upper
gastrointestinal symptoms in outpatients with osteoporosis
previously treated with daily or weekly bisphosphonate
products.
Introduction The purposes of this study were to investigate
the effects of once-monthly oral minodronate (MIN 50mg) on
bone turnover markers and bone mineral density, low back
pain, and upper gastrointestinal symptoms, as well as prefer-
ence for and treatment persistence of MIN 50 mg among
Japanese osteoporosis patients currently treated with daily or
weekly bisphosphonates.
Methods Study patients were allocated based on their prefer-
ence to either the Switch group (patients willing to switch over
to MIN 50 mg) or the Continue group (patients wanting to
continue their current therapies). Patients’ treatment persis-
tence and satisfaction levels with the therapies were assessed
using a self-administered questionnaire. The study endpoints
were serum TRACP-5b, serum P1NP, bone mineral density,
upper gastrointestinal symptoms, and low back pain.
Results In total, 264 and 133 patients were allocated into the
Switch and Continue groups, respectively. Approximately,
65 % of patients were willing to switch to MIN 50 mg, with
A. Sakai (*)
Department of Orthopaedic Surgery, School of Medicine, University
of Occupational and Environmental Health, 1-1 Iseigaoka,
Yahatanishi-ku, Kitakyushu 807-8555, Japan
e-mail: a-sakai@med.uoeh-u.ac.jp
S. Ikeda
Department of Orthopaedic Surgery, Ken-Ai Memorial Hospital,
Onga, Japan
N. Okimoto
Okimoto Clinic, Kure, Japan, Okamoto Orthopaedics and Sports
Clinic, Hiroshima, Japan
H. Matsumoto
Department of Orthopaedic Surgery, Sanzai Hospital, Saito, Japan
K. Teshima
Teshima Orthopaedic Clinic, Kitakyushu, Japan
Y. Okazaki
Department of Orthopaedic Surgery, Makiyama Central Hospital,
Fukuoka, Japan
F. Fukuda
Department of Orthopaedic Surgery, Kitakyushu General Hospital,
Kitakyushu, Japan
S. Arita
Department of Orthopaedic Surgery, Obase Hospital, Miyako, Japan
H. Tsurukami
Tsurukami Clinic of Orthopaedic and Rheumatology,
Kumamoto, Japan
M. Nagashima
Katsuki Neurosurgery and Orthopaedic Clinic, Nogata, Japan
T. Yoshioka
Department of Orthopaedic Surgery, Sakamidorii Hospital,
Hiroshima, Japan
Osteoporos Int (2014) 25:2245–2253
DOI 10.1007/s00198-014-2756-8
the predominant reason being “less frequent dosing more
convenient.” Treatment persistence was significantly higher
in the Switch group (MIN 50 mg) than the Continue group.
Almost all patients with abnormal bone metabolism markers
demonstrated normalization after switchover. MIN 50 mg
alleviated low back pain and upper gastrointestinal symptoms
induced by prior bisphosphonate use.
Conclusions MIN 50 mg alleviates low back pain, reduces
bone turnover markers and increases bone density, and in-
duces fewer upper gastrointestinal symptoms after switchover
from prior bisphosphonate products, and therefore, it may
provide patients with a more convenient treatment option
and enhance long-term treatment persistence.
Keywords Bonemineral density . Minodronate . Once
monthly . Persistence . Preference . TRACP-5b
Introduction
Bisphosphonates (BPs) are recommended as a first-line agent
for osteoporosis treatment by many national and international
guidelines [1–3]. However, the treatment persistence rate of BPs
is far from satisfactory owing to its complex administration
regimen and patients’ poor awareness levels of osteoporosis
[4–9]. New drug formulations with less frequent dosing to
resolve these problems have been developed, and weekly BP
products have becomemainstream in Japan, while monthly BPs
are already familiar outside Japan. In September 2011, the first
novel, once-monthly 50 mg formulation of minodronate (MIN
50 mg) was approved and marketed in Japan.
Minodronate is a third-generation bisphosphonate agent
containing nitrogen [10] and approved for use for the treatment
of osteoporosis in Japan [11]. Its mechanism of action involves
inhibition of farnesyl pyrophosphate synthase activity [12], and
therefore, MIN 50 mg shows strong inhibitory effects on bone
resorption [13]. In an earlier clinical study, Okazaki et al. [14]
reported that monthly minodronate at a dose of 30 or 50mg had
comparable efficacy to 1 mg daily administration in terms of
change in bone mineral density (BMD) and bone turnover
markers, with similar safety profiles.
The purposes of this multi-center, prospective, open-label,
observational study were to investigate (1) the effects of once-
monthly oral BP (MIN 50 mg) on bone turnover markers and
bone mineral density (BMD), (2) analgesic effects of MIN
50 mg on low back pain (LBP) and upper gastrointestinal (GI)
symptoms, and (3) preference for and treatment persistence of
MIN 50 mg among Japanese patients with osteoporosis cur-
rently treated with daily or weekly bisphosphonates. Based on
the findings of this study, we discuss the contribution of the
once-monthly product to improving treatment persistence in
outpatients with osteoporosis compared to treatment with
conventional BP products.
Material and methods
This study was approved by the institutional review board at
each participating study site. Prior to commencing any study
procedure, the purposes and methods of this study were ex-
plained to all participants, and their written informed consent
was obtained.
Study design
This observational study was conducted based on a multi-
center, prospective, open-label, parallel-group comparison de-
sign, in outpatients with osteoporosis currently treated with
daily or weekly BPs, at 11 institutions in Japan. A question-
naire form was used for data collection.
A total of 397 patients were enrolled in the study from
October 2011 to April 2012 and asked their preference for
once-monthly oral bisphosphonate for group allocation.
Registered patients were allocated based on their answered
preferences to either the “Switch” group (n=264), consisting
of patients who were willing to switch over to MIN 50 mg
from their current therapies, or the “Continue” group (n=133),
consisting of patients who wanted to continue their current
therapies (Fig. 1).
Study endpoints and schedule
The study endpoints were measured according to the follow-
ing schedule: serum TRACP-5b (courtesy of DS Pharma
Biomedical Co., Ltd., Tokyo, Japan), a bone resorption mark-
er, at baseline and at 1, 2, and 6 months after the start of the
study; serum P1NP, a bone formation marker, at baseline and
at 2 and 6 months after the start of the study; and BMD of the
lumbar spine, total hip, femoral neck, and/or 1/3 distal radius,
at baseline and at 6 months after the start of the study. Upper
GI symptoms were assessed by patients using a six-point
symptom severity scale, and LBP was evaluated using a
100-mm visual analogue scale (VAS) and five items in the
pain domain score of the Japanese Osteoporosis Quality of
Life (JOQOL) Questionnaire [15]. Patients’ treatment persis-
tence and satisfaction levels with the therapies were assessed
using a self-administered questionnaire.
The self-administered questionnaire included the fol-
lowing items: (1) patient preference for once-monthly
BP (MIN 50 mg) and the reason for willingness or
unwillingness to switch to MIN 50 mg; (2) desire for
improvement over current BP treatment; (3) patient per-
sistence with current BP treatment; (4) patient persis-
tence with MIN 50 mg over 6 months; and (5) satis-
faction level in patients treated with MIN 50 mg and
the reason for willingness to continue the medication.
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Statistical analysis
All obtained data were statistically analyzed by one author
(AS) using JMP software ver. 8.2 (SAS Institute, Cary, NC,
USA). Continuous variables were summarized as mean±stan-
dard deviation (SD), and categorical data were summarized as
frequency and percentage (%). Time course comparisons from
baseline were evaluated using the Wilcoxon signed-rank test,
group comparisons at specific time points using the Wilcoxon
rank-sum test or Student’s t test, and comparisons of inci-
dences using the chi-square test or Fisher’s exact test. To
assess treatment persistence, the data were illustrated as
Kaplan-Meier survival curves according to treatment group
and were analyzed using the log-rank test. All statistical tests
were conducted with a significance level of α=0.05, and no
multiplicity adjustment was applied.
Results
A total of 397 patients using BPs for the treatment of osteo-
porosis were enrolled in the study. Study patients were divided
into two study groups depending on their preference: patients
in the Switch group (n=264) were switched over to once-
monthly minodronate (MIN 50mg), and those in the Continue
group (n=133) continued treatment with their current daily or
weekly BP.
Baseline characteristics of study patients
The demographic and baseline characteristics of study patients
are summarized in Table 1. Overall, patients’ mean age was
76.0 years (range 54–98 y), and almost all study patients were
female (94.2 %). The current bisphosphonate medication at
baseline was predominantly a once-a-week product (78.8 %).
Nearly half of patients (46.6 %) had concomitant diseases,
including hypertension, hyperlipidemia, and diabetesmellitus.
The most common concomitant medications were vitamin D
analogues (57.7 %) and calcium agents (28.5 %).
No significant differences were observed in the demo-
graphic characteristics of the Switch and Control groups.
Among baseline characteristics, no significant differences
were observed between the Switch and the Continue groups,
except the VAS score for back pain (27.9±20.8 in the Switch
group vs. 22.6±20.7 in the Continue group; p=0.010).
With no statistically significant differences in the demo-
graphic and baseline characteristics between the groups,
within-group comparisons were then conducted.
Patient preference and treatment persistence
Of 397 study patients, 264 (66.5 %) were willing to
switch to MIN 50 mg, and 133 (33.5 %) were not
willing to switch their current BP products. This trend,
with two-thirds of patients willing to switch, was con-
sistent across patients taking either daily or weekly BPs.
In the daily dose subgroup, older patients showed a
tendency to keep their current BP products. The most
common reasons for willingness to switch to MIN
50 mg were “less frequent dosing more convenient”
(87.3 %) followed by “easier to remember to take
medication” (54.8 %). By contrast, the most common
reasons for unwillingness to switch to MIN 50 mg were







Questionnaire a): Are 
you willing to switch 
to once-monthly BP 





MIN 50 mg Switch Group (n=264)
Prior BP Continue Group (n=133)







a): Patients were asked to complete self-administered questionnaire on the following items:
(1) Patient preference for once-monthly BP (MIN 50 mg), and the reason for willingness or unwillingness to switch to MIN 50 mg
(2) Desire for improvement over current BP treatment
(3) Persistence of current BP treatment
b): Bone turnover markers (TRACP-5b and P1NP) were evaluated only in the Switch group.
c): Abdominal symptom-related QOL was evaluated using the Izumo scale [16], a questionnaire to assess quality of life in patients in
patients with gastrointestinal symptoms.
Fig. 1 Study design and
schedule. a Patients were asked to
complete a self-administered
questionnaire on the following
items: (1) Patient preference for
once-monthly BP (MIN 50 mg)
and the reason for willingness or
unwillingness to switch to MIN
50 mg. (2) Desire for
improvement over current BP
treatment. (3) Persistence of
current BP treatment. b Bone
turnover markers (TRACP-5b
and P1NP) were evaluated only in
the Switch group. c Abdominal
symptom-related QOL was
evaluated using the Izumo scale
[16], a questionnaire to assess
quality of life in patients with
gastrointestinal symptoms
Osteoporos Int (2014) 25:2245–2253 2247
Table 1 Demographic and baseline characteristics of study patients










































































































































NSAIDs 66 (16.6 %) 45 (17.0 %) 21 (15.8 %) N. S.
Glucocorticoids 3 (0.8 %) 3 (1.1 %) 0 (0.0 %) N. S.
Baseline characteristics
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followed by “more chance to miss taking medication”
(29.3 %) and “being satisfied with current BP”
(27.8 %). The relationship between patients’ willingness
to switch to MIN 50 mg and persistence of their prior
BPs was investigated, revealing that patients who some-
times (n=91) or often (n=7) missed taking their current
BPs (83.7 %, 82 of 98) were more willing to switch to
MIN 50 mg than those who were completely persistent
with their current BP regimen (60.8 %, 178 of 293)
(p<0.001).
Response to once-monthly minodronate
The early responses to once-monthly minodronate (MIN
50 mg) were evaluated by comparisons within the Switch
group (change over time) or between the Switch and
Continue groups.
Changes in BMD after 6 months of treatment (Fig. 2)
BMD in the Switch group, evaluated as the percentage of
young adult mean values (YAM%), was significantly in-
creased in the lumbar spine (1.5 %, p<0.001) and distal radius
(1.1 %, p<0.01). In the subgroups of patients who switched
from alendronate and risedronate, BMD was significantly
increased in the lumbar spine (+1.1 %, p<0.001 and +2.3 %,
p<0.01, respectively). In the subgroup of patients who
switched from daily doses of minodronate, BMD was signif-
icantly increased in the lumbar spine (+3.2 %, p<0.01). By
contrast, no significant changes were observed in BMD in the
total hip or the femoral neck in the Continue group or any of
its subgroups.
Table 1 (continued)










Data are expressed as mean±standard deviation unless otherwise indicated
BMI body mass index, Diabetes M. diabetes mellitus, PPI proton pump inhibitor, NSAID non-steroidal anti-inflammatory drug, VAS visual analogue
scale, BMD bone mass density, YAM young adult mean
†Comparison between Switch group and Continue group
*Statistically significant (α=0.05) as analyzed by Wilcoxon rank-sum test




(YAM %)(YAM %) (YAM %)
(n=167) (n=80) (n=56) (n=88) (n=45) (n=15)(n=51) (n=62)
Lumbar spine Total hip Distal radiusFemoral neck
:at baseline :at 6months
Fig. 2 Changes in BMD after 6 months of treatment. YAM% young adult mean (%) **p<0.01; ***p<0.001, significantly different from baseline as
analyzed by Wilcoxon signed-rank test
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Changes in bone metabolism markers after 6 months of treat-
ment (Fig. 3)
In the Switch group, the levels of the bone marker
TRACP-5b (reference range 120 to 420 mU/dL) signif-
icantly reduced within 1 month after treatment
(−10.2 %, p<0.001) and at subsequent time points.
Especially in the subgroup of patients with a higher
baseline TRACP-5b (over 420 mU/dL), TRACP-5b de-
creased rapidly (by approximately 30 %) into the refer-
ence range within 1 month after treatment. By contrast,
in the subgroup of patients with normal baseline
TRACP-5b levels, values were maintained within the
reference range without any unwanted reductions
throughout the study period.
A subgroup analysis was conducted for each prior BP
medication. Patients with a high baseline TRACP-5b level
(>420 mU/dL) in the subgroup switched over from
alendronate showed the same trend as the Switch group over-
all, with a reduction of approximately 25 %. In the subgroup
switched from risedronate, a larger reduction of approximately
35 % was observed. In the subgroup switched from a daily
dose of minodronate, a marked reduction of approximately
45 % was observed but was not statistically significant due to
the small number of patients.
The bone marker P1NP (reference range 14.9 to
68.8 μg/L) was also significantly reduced within
2 months after treatment (−8.4 %, p<0.001) and at
subsequent time points. Especially in the subgroup of
patients with a higher baseline P1NP (over 68.8 μg/L),
P1NP decreased rapidly (approximately 55 %) into the
reference range within 2 months after treatment. Similar
to TRACP-5b, in the subgroup of patients with a nor-
mal baseline P1NP, values were maintained in the ref-
erence range without any unwanted reductions through-
out the study period.
Changes in low back pain and upper gastrointestinal
symptoms
Low back pain is well known as a common symptom of
osteoporosis, and upper GI symptoms are common adverse
drug reactions to BPs.
Fig. 3 Time course of change in TRACP-5b (upper) and P1NP (bottom) after switchover toMIN 50mg. Data were evaluated in patients who completed
the 6-month measurements. ***p<0.001; *p<0.05, significantly different from baseline as analyzed by Wilcoxon signed-rank test
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Changes in low back pain after 6 months of treatment
(Fig. 4)
Low back pain was evaluated in patients with a base-
line VAS score of 10 mm or more who completed all
scheduled VAS measurements. The Switch and Continue
groups consisted of 145 and 44 patients, respectively. The
baseline mean VAS scores were 36.0±16.0 mm in the
Switch group and 32.0±18.0 mm in the Continue group,
which were significantly different (p=0.046).
In the Switch group, VAS scores for low back pain signif-
icantly improved 1 month after treatment and at subsequent
time points (p<0.001). Also, the Switch group showed sig-
nificantly greater decreases from baseline than the Continue
group at 1 month after treatment and subsequent time points
(p<0.001). By contrast, in the Continue group, the VAS scores
were stable, and therefore, the mean changes from baseline
were not statistically significant throughout the study.
Subgroup analysis was conducted for each prior BP
treatment (alendronate, risedronate, or daily dose of
minodronate). In all subgroups, VAS scores demonstrat-
ed a decreasing trend after switching, with the decreases
in the subgroups of patients who switched from
alendronate and daily dose of minodronate statistically
significant at 1 month after treatment and subsequent
time points (p<0.05). The Switch group showed signif-
icantly greater decreases from baseline than the
Continue group only for the subgroup of patients who
switched from alendronate.
Changes in upper gastrointestinal symptoms after 6 months of
treatment (data not shown) Upper GI symptoms (heartburn,
epigastralgia, and epigastric fullness) were evaluated using the
Izumo scale questionnaire [16].
At baseline, a higher percentage of patients who switched
over from alendronate had GI symptoms compared to those
who switched over from risedronate or daily doses of
minodronate. The use of concomitant gastrointestinal agents
for GI symptoms was similar among the prior BP treatment
subgroups, with no significant differences.
In the Switch group, the mean Izumo scale scores for the
three GI symptoms significantly improved 1 month after
treatment and at subsequent time points (p<0.05), with the
exception of epigastric fullness at 2 months after treatment. By
contrast, in the Continue group, the mean Izumo scale scores
for epigastralgia and epigastric fullness were stable over the 6-
month study period, while the mean scores for heartburn
tended to improve, with statistically significant differences at
3 and 6 months after treatment compared to baseline (p<0.05
and p<0.01, respectively).
Treatment persistence of MIN 50 mg
Treatment persistence in the Switch and Continue groups
during the 6-month study period in summarized using survival
curves in Fig. 5. Overall, the persistence rate after 6 months of
treatment was higher in the Switch group (89.8 %) than that in
the Continue group (78.9 %; p<0.003, log-rank test). During
Fig. 4 Time course of change in
back pain VAS score: a mean
values at each evaluation point
and b mean changes from
baseline. VAS scores were
evaluated in patients with baseline




from values in the Continue group
as analyzed by Wilcoxon rank-
sum test, ***p<0.001,
significantly different from
baseline as analyzed byWilcoxon
signed-rank test
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the study period, 9 patients (3.4 %) in the Switch group hoped
to switch back to their previous BP products, while 19 patients
(14.3 %) in the Continue group hoped to switch over to MIN
50 mg. Regarding expectations (baseline) and actual impres-
sions (after 6 months of treatment) of the once-monthly reg-
imen, 87.3 % of patients (220 of 252) expected less frequent
dosing to be more convenient, and 77.9 % of patients (180 of
231) actually had such an impression. However, the impres-
sion that “monthly schedule fits lifestyle better” drastically
increased from baseline (5.6 %, 14 of 252) to the end of the
study (32.5 %, 75 of 231).
Discussion
We conducted a questionnaire-based study on drug preference
for once-monthly oral bisphosphonate (MIN 50 mg) and
persistence of MIN 50 mg in Japanese patients with osteopo-
rosis currently treated with daily or weekly BPs. Based on
patients’ preference, study patients were allocated to either the
“Switch” group, consisting of patients who were willing to
switch over to MIN 50 mg from their current therapies, or the
“Continue” group, consisting of patients who wanted to con-
tinue their current therapies. The bone mineral densities, bone
turnover markers, time courses of low back pain and upper GI
symptoms, and treatment persistence were compared between
the treatment groups to evaluate the usefulness of once-
monthly MIN 50 mg treatment.
About 65 % of study patients were willing to switch to
MIN 50 mg among both patients treated with daily BPs and
weekly BPs. In addition, at the end of the study, almost all of
the study patients in the Switch group responded via ques-
tionnaire that they were “willing to continue MIN 50 mg.”
Once-monthly treatments such as MIN 50 mg will be a
powerful option for these patients. Indeed, the treatment per-
sistence of MIN 50 mg was significantly higher than that in
the Continue group consisting of patients treated with daily or
weekly BP products, and therefore, the once-monthly treat-
ment should improve patient persistence.
Almost all the patients treated with BP products whose
bone turnover marker levels exceeded the normal range at
baseline achieved normal levels after switching toMIN 50mg
(Fig. 3). This finding suggests a superior bone resorption
inhibitory effect of MIN 50 mg. In addition, MIN 50 mg
was not associated with an unwanted reduction in bone turn-
over markers among patients whose marker levels were al-
ready normal, indicating that MIN 50 mg treatment is an ideal
solution for improving bone turnover markers.
While many reports have indicated the bone density-
increasing effects of switching to daily minodronate from other
BPs [11, 17–19], our study further confirmed that switching to
once-monthly minodronate from other BPs significantly in-
creased the bone density of the lumbar spine and distal radius
(Fig. 2), suggesting that once-monthly minodronate 50 mg will
be a powerful alternative for osteoporosis treatment.
While daily minodronate has been reported to alleviate low
back pain [19], this study revealed that once-monthly MIN
50 mg also achieved positive results. Prompt effects of MIN
50 mg on low back pain after switchover from prior BPs
(Fig. 4) suggest the contribution of minodronate-specific in-
hibitory action on the P2X2/3 receptor [20, 21], which is
expressed in primary sensory neurons that mediate
nociception and are implicated in neuropathic and inflamma-
tory pain responses [22].
We have already reported that daily minodronate treatment
induced fewer GI symptoms in comparison with weekly
alendronate treatment [19]. As expected from this prior report,
the GI symptoms induced by weekly alendronate were re-
solved statistically significantly within 1 month after
switchover from alendronate to MIN 50 mg (data not shown),
suggesting that once-monthly minodronate may also induce
fewer GI symptoms (heartburn, epigastralgia, and epigastric
fullness). MIN 50 mg is highly likely to improve both conve-
nience and treatment persistence because it alleviates low
back pain and results in fewer GI symptoms after switchover
from conventional BP products.
There are limitations in this study. This is an open-label
observational study involving small number of patients, and
the patients are not randomized but are assigned to two groups
by their preference. Therefore, there is a selection bias in being
enrolled in the two groups.
Fig. 5 Treatment persistence in the Switch and Continue groups. Pro-
portion of persistent patients for each treatment was evaluated at 1, 2, 3,
and 6 months of treatment. **p<0.01, significantly different between
groups as analyzed by log-rank test
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Because MIN 50 mg alleviates low back pain, reduces
bone turnover markers, increases bone mineral density and
treatment persistence, and induces fewer GI symptoms after
switchover from conventional BP products, the drug may
provide patients with a more convenient treatment option
and enhance long-term treatment persistence with the therapy.
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